
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 915 | 915 | 1132 | 1704 | 3512 | 3823 |
Fund Return | -8.49% | -8.49% | 13.23% | 19.44% | 28.56% | 14.35% |
Place in category | 47 | 47 | 67 | 30 | 24 | 3 |
% in Category | 58 | 58 | 79 | 35 | 42 | 9 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Small Cap Fund Bonus | 508.26B | -14.18 | 20.68 | 20.04 | ||
Reliance Small Cap Fund Dividend | 508.26B | -14.80 | 19.86 | 20.27 | ||
Reliance Small Cap Fund Growth | 508.26B | -14.18 | 20.68 | 20.04 | ||
Reliance Small Cap Fund Dir Bon | 508.26B | -14.03 | 21.69 | 21.19 | ||
Reliance Small Cap Fund Dir Gr | 508.26B | -14.56 | 21.03 | 21.42 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Pharma Fund - Bonus | 76.37B | -8.69 | 18.38 | 13.34 | ||
Reliance Pharma Dividend Payout | 76.37B | -9.44 | 17.76 | 14.28 | ||
Reliance Pharma Fund - Growth | 76.37B | -8.69 | 18.38 | 13.34 | ||
Reliance Pharma Direct Growth | 76.37B | -8.49 | 19.44 | 14.35 | ||
Reliance Pharma Dir Div Payout | 76.37B | -9.15 | 18.99 | 15.11 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Sun Pharma | INE044A01036 | 13.68 | 1,693.10 | -0.70% | |
Divi's Labs | INE361B01024 | 9.32 | 5,754.00 | +0.34% | |
Lupin | INE326A01037 | 7.73 | 1,934.20 | -3.91% | |
Cipla | INE059A01026 | 5.90 | 1,496.40 | +0.99% | |
Dr Reddy’s Laboratories | INE089A01031 | 5.35 | 1,158.40 | +0.30% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | BUY | Strong Buy |
Summary | Buy | Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review